Andreia Carvalho

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5128995/publications.pdf

Version: 2024-02-01

20 papers	848 citations	623188 14 h-index	752256 20 g-index
22 all docs	22 docs citations	22 times ranked	1424 citing authors

#	Article	IF	Citations
1	Neuron-specific proteotoxicity of mutant ataxin-3 in C. elegans : rescue by the DAF-16 and HSF-1 pathways. Human Molecular Genetics, 2011, 20, 2996-3009.	1.4	101
2	Secretome of Mesenchymal Progenitors from the Umbilical Cord Acts as Modulator of Neural/Glial Proliferation and Differentiation. Stem Cell Reviews and Reports, 2015, 11, 288-297.	5.6	100
3	Liver transplantation in transthyretin amyloidosis: Issues and challenges. Liver Transplantation, 2015, 21, 282-292.	1.3	97
4	Chronic Treatment with 17-DMAG Improves Balance and Coordination in A New Mouse Model of Machado-Joseph Disease. Neurotherapeutics, 2014, 11, 433-449.	2.1	86
5	The Role of the Mammalian DNA End-processing Enzyme Polynucleotide Kinase 3â€™-Phosphatase in Spinocerebellar Ataxia Type 3 Pathogenesis. PLoS Genetics, 2015, 11, e1004749.	1.5	84
6	Dysregulation of autophagy and stress granule-related proteins in stress-driven Tau pathology. Cell Death and Differentiation, 2019, 26, 1411-1427.	5.0	80
7	Serotonergic signalling suppresses ataxin 3 aggregation and neurotoxicity in animal models of Machado-Joseph disease. Brain, 2015, 138, 3221-3237.	3.7	74
8	The Secretome of Bone Marrow and Wharton Jelly Derived Mesenchymal Stem Cells Induces Differentiation and Neurite Outgrowth in SH-SY5Y Cells. Stem Cells International, 2014, 2014, 1-10.	1.2	38
9	Dominant negative effect of polyglutamine expansion perturbs normal function of ataxin-3 in neuronal cells. Human Molecular Genetics, 2015, 24, 100-117.	1.4	26
10	Neuroprotective Effects of Creatine in the CMVMJD135 Mouse Model of Spinocerebellar Ataxia Type 3. Movement Disorders, 2018, 33, 815-826.	2.2	26
11	Absence of Ataxin-3 Leads to Enhanced Stress Response in C. elegans. PLoS ONE, 2011, 6, e18512.	1.1	26
12	Lithium Chloride Therapy Fails to Improve Motor Function in a Transgenic Mouse Model of Machado-Joseph Disease. Cerebellum, 2014, 13, 713-727.	1.4	25
13	Limited Effect of Chronic Valproic Acid Treatment in a Mouse Model of Machado-Joseph Disease. PLoS ONE, 2015, 10, e0141610.	1.1	22
14	Selective impact of Tau loss on nociceptive primary afferents and pain sensation. Experimental Neurology, 2014, 261, 486-493.	2.0	15
15	ATX-3, CDC-48 and UBXN-5: A new trimolecular complex in Caenorhabditis elegans. Biochemical and Biophysical Research Communications, 2009, 386, 575-581.	1.0	13
16	Levetiracetam treatment leads to functional recovery after thoracic or cervical injuries of the spinal cord. Npj Regenerative Medicine, 2021, 6, 11.	2.5	10
17	Polyglutamine spinocerebellar ataxias: emerging therapeutic targets. Expert Opinion on Therapeutic Targets, 2020, 24, 1099-1119.	1.5	8
18	Preclinical Assessment of Mesenchymal-Stem-Cell-Based Therapies in Spinocerebellar Ataxia Type 3. Biomedicines, 2021, 9, 1754.	1.4	5

#	Article	IF	Citations
19	Cerebellar neuronal dysfunction accompanies early motor symptoms in spinocerebellar ataxia type 3. DMM Disease Models and Mechanisms, 2022, 15, .	1.2	5
20	Profiling Microglia in a Mouse Model of Machadoâ€“Joseph Disease. Biomedicines, 2022, 10, 237.	1.4	3